Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
View Patent ↗Novel dopamine receptor ligands of the formula: pharmaceutical formulations of such compounds, and a method using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system, are described. The compounds are expected to be useful in treating Parkinson's disease, improving cognition, improving memory, improving the negative symptoms of schizophrenia, improving attention-deficit hyperactivity disorder and related developmental disorders, treating substance abuse disorders, and in treating various peripheral conditions where changes in dopamine receptor occupation affects physiological function, including organ perfusion, cardiovascular function, and selected endocrine and immune system functions.
1. A method for treating a patient having a dopamine-related dysfunction of the central nervous system selected from the group consisting of attention deficit disorder, attention-deficit hyperactivity disorder, narcolepsy, cognitive disorders, memory disorders, schizophrenia, substance abuse disorders, and negative symptoms of schizophrenia, said method comprising the step of administering to said patient in need thereof an effective amount of a compound of the formula:
which activates both D 1 and D 4 dopamine receptors.
2. The method of claim 1 wherein the compound administered binds to both D 1 and D 4 dopamine receptors with a K 0.5 of less than about 1 μM.
3. A method for treating a patient having a dopamine-related dysfunction of the central nervous system selected from the group consisting of attention deficit disorder, attention-deficit hyperactivity disorder, narcolepsy, cognitive disorders, memory disorders, schizophrenia, substance abuse disorders, and negative symptoms of schizophrenia, said method comprising the step of administering to said patient in need thereof an effective amount of a compound of the formula:
which activates both D 1 and D 4 dopamine receptors;
wherein:
R 1 , R 2 and R 3 are hydrogen, C 1 -C 4 alkyl, or C 2 -C 4 alkenyl;
R 8 is hydrogen, C 1 -C 4 alkyl, or a phenoxy protecting group;
X 9 is hydrogen, halo, or a group of the formula —OR wherein R is hydrogen, C 1 -C 4 alkyl, or a phenoxy protecting group, and further when X 9 is a group of the formula —OR, the groups R and R 8 can be taken together to form a group of the formula —CH 2 —;
R 4 , R 5 , and R 6 , are independently selected from the group consisting of hydrogen, C 1 -C 4 alkyl, phenyl, halo, or a group —OR wherein R is as defined above;
or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 wherein X 9 is hydroxy and R 8 is hydrogen.
5. The method of claim 3 wherein R 1 , R 2 , and R 3 are hydrogen.
6. The method of claim 4 wherein R 1 , R 2 , and R 3 are hydrogen.
7. The method of claim 3 wherein R 1 , R 3 , R 4 , R 5 and R 6 are each hydrogen.
8. The method of claim 3 wherein X 9 and R 8 are hydrogen.
9. The method of claim 3 wherein R 1 and R 3 are hydrogen.
10. The method of claim 3 wherein R 1 and R 3 are C 1 -C 4 alkyl.
11. The method of claim 3 wherein R 2 is C 1 -C 4 alkyl or C 2 -C 4 alkenyl.
12. The method of claim 3 wherein the compound administered binds to both D 1 and D 4 dopamine receptors with a K 0.5 of less than about 1 μM.